Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients
暂无分享,去创建一个
G. Laurent | C. Récher | L. Obéric | L. Ysebaert | B. Hébraud | E. Suc | P. Houyau | W. Vaillant